Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michal Shteinberg

Showing results (91-100 of 143) with videos related to

Pageof 15
Sort By:
Respiratory Medicine|September 27, 2017
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experienceAdi Dagan, Malena Cohen-Cymberknoh, Michal Shteinberg, et al.
The European Respiratory Journal|June 6, 2024
Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient surveyArietta Spinou, Marta Almagro, Bridget Harris, et al.
The European Respiratory Journal|September 10, 2024
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding studyJames D Chalmers, Michal Shteinberg, Marcus A Mall, et al.
The European Respiratory Journal|February 2, 2018
The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasisDavid Araújo, Michal Shteinberg, Stefano Aliberti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 5, 2016
Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosisMalena Cohen-Cymberknoh, Noa Gilead, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsCharles S Haworth, Michal Shteinberg, Kevin Winthrop, et al.
ERJ Open Research|November 25, 2021
ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working GroupLetizia Traversi, Marc Miravitlles, Miguel Angel Martinez-Garcia, et al.
American Journal of Respiratory and Critical Care Medicine|January 23, 2018
Characterization of the "Frequent Exacerbator Phenotype" in BronchiectasisJames D Chalmers, Stefano Aliberti, Anna Filonenko, et al.
Chest|November 4, 2024
Clinical Efficacy of Serum Antiglycopeptidolipid Core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Chloe Hughes, Zsofia Eke, et al.
American Journal of Respiratory and Critical Care Medicine|September 28, 2023
Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Soorack Ryu, Holly R Keir, et al.
Pageof 15

Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Respiratory Medicine|September 27, 2017
Ivacaftor for the p.Ser549Arg (S549R) gating mutation - The Israeli experienceAdi Dagan, Malena Cohen-Cymberknoh, Michal Shteinberg, et al.
The European Respiratory Journal|June 6, 2024
Diagnostic delay and access to care in bronchiectasis: data from the EMBARC/ELF patient surveyArietta Spinou, Marta Almagro, Bridget Harris, et al.
The European Respiratory Journal|September 10, 2024
Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF, a phase II randomised, double-blind, placebo-controlled, dose-finding studyJames D Chalmers, Michal Shteinberg, Marcus A Mall, et al.
The European Respiratory Journal|February 2, 2018
The independent contribution of <i>Pseudomonas aeruginosa</i> infection to long-term clinical outcomes in bronchiectasisDavid Araújo, Michal Shteinberg, Stefano Aliberti, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|May 5, 2016
Eradication failure of newly acquired Pseudomonas aeruginosa isolates in cystic fibrosisMalena Cohen-Cymberknoh, Noa Gilead, Silvia Gartner, et al.
The Lancet. Respiratory Medicine|September 13, 2024
Inhaled colistimethate sodium in patients with bronchiectasis and Pseudomonas aeruginosa infection: results of PROMIS-I and PROMIS-II, two randomised, double-blind, placebo-controlled phase 3 trials assessing safety and efficacy over 12 monthsCharles S Haworth, Michal Shteinberg, Kevin Winthrop, et al.
ERJ Open Research|November 25, 2021
ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working GroupLetizia Traversi, Marc Miravitlles, Miguel Angel Martinez-Garcia, et al.
American Journal of Respiratory and Critical Care Medicine|January 23, 2018
Characterization of the "Frequent Exacerbator Phenotype" in BronchiectasisJames D Chalmers, Stefano Aliberti, Anna Filonenko, et al.
Chest|November 4, 2024
Clinical Efficacy of Serum Antiglycopeptidolipid Core IgA Antibody Test for Screening Nontuberculous Mycobacterial Pulmonary Disease in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Chloe Hughes, Zsofia Eke, et al.
American Journal of Respiratory and Critical Care Medicine|September 28, 2023
Inflammatory Molecular Endotypes in Bronchiectasis: A European Multicenter Cohort StudyHayoung Choi, Soorack Ryu, Holly R Keir, et al.
Pageof 15